No description available.

Reversible protein phosphorylation is an essential component of metazoan signaling and cardiovascular physiology. Protein kinase activity is required for regulation of cardiac ion channel and membrane receptor function, metabolism, and transcription, and aberrant kinase function is widely observed across disparate cardiac pathologies. In fact, multiple generations of cardiac therapies (eg. beta-adrenergic receptor blockers) have targeted cardiac kinase regulatory cascades. In contrast, essentially nothing is known regarding the mechanisms that regulate cardiac phosphatase activity at baseline or in cardiovascular disease. Protein phosphatase 2A (PP2A) is a key phosphatase with multiple roles in cardiac physiology. Here we demonstrate the surprisingly complex regulatory platforms that control PP2A holoenzyme activity in heart. We present the first full characterization of the expression and regulation of the PP2A family of polypeptides in heart. We identify the expression of seventeen different PP2A genes in human heart and define their differential expression and distribution across species and in different cardiac chambers. We show unique subcellular distributions of PP2A regulatory subunits in myocytes, strongly implicating the regulatory subunit in conferring PP2A target specificity in vivo. We report striking differential regulation of PP2A scaffolding, regulatory, and catalytic subunit expression in multiple models of cardiovascular disease as well as in human heart failure samples. Importantly, we demonstrate that PP2A regulation in disease extends far beyond expression and subcellular location, by identifying and describing differential post-translational modifications of the PP2A holoenzyme in human heart failure. Furthermore, we go to characterize a mechanism for this method of post-translational modification that may represent a pathway capable of being therapeutically manipulated in human heart failure. Lastly we provide evidence that dysregulation of phosphatase activity contributes to the cellular pathology associated with a previously described inheritable human arrhythmia syndrome, highlighting the importance of the PP2A in cardiovascular physiology and disease. Together, our findings provide new insight into the functional complexity of PP2A expression, activity, and regulation in heart and in human cardiovascular disease and identify potentially new and specific gene and subcellular targets for the treatment of human arrhythmia and heart failure.

Reversible protein phosphorylation is an essential component of metazoan signaling and cardiovascular physiology. Protein kinase activity is required for regulation of cardiac ion channel and membrane receptor function, metabolism, and transcription, and aberrant kinase function is widely observed across disparate cardiac pathologies. In fact, multiple generations of cardiac therapies (eg. beta-adrenergic receptor blockers) have targeted cardiac kinase regulatory cascades. In contrast, essentially nothing is known regarding the mechanisms that regulate cardiac phosphatase activity at baseline or in cardiovascular disease. Protein phosphatase 2A (PP2A) is a key phosphatase with multiple roles in cardiac physiology. Here we demonstrate the surprisingly complex regulatory platforms that control PP2A holoenzyme activity in heart. We present the first full characterization of the expression and regulation of the PP2A family of polypeptides in heart. We identify the expression of seventeen different PP2A genes in human heart and define their differential expression and distribution across species and in different cardiac chambers. We show unique subcellular distributions of PP2A regulatory subunits in myocytes, strongly implicating the regulatory subunit in conferring PP2A target specificity in vivo. We report striking differential regulation of PP2A scaffolding, regulatory, and catalytic subunit expression in multiple models of cardiovascular disease as well as in human heart failure samples. Importantly, we demonstrate that PP2A regulation in disease extends far beyond expression and subcellular location, by identifying and describing differential post-translational modifications of the PP2A holoenzyme in human heart failure. Furthermore, we go to characterize a mechanism for this method of post-translational modification that may represent a pathway capable of being therapeutically manipulated in human heart failure. Lastly we provide evidence that dysregulation of phosphatase activity contributes to the cellular pathology associated with a previously described inheritable human arrhythmia syndrome, highlighting the importance of the PP2A in cardiovascular physiology and disease. Together, our findings provide new insight into the functional complexity of PP2A expression, activity, and regulation in heart and in human cardiovascular disease and identify potentially new and specific gene and subcellular targets for the treatment of human arrhythmia and heart failure.

Ankyrin-B (Ank-B) is a crucial scaffolding protein regulating expression and localization of contractile machinery in the cardiac muscle. Recent genetic investigations in the First Nations Community, the Gitxsan of Northern BC, identified a mutation in Ank-B (p.S646F c.1937 C>T) associated with a cardiac arrhythmia, Long QT Syndrome Type 4 (LQTS4). Distinct from other LQTS4 subtypes, individuals harbouring the p.S646F variant exhibit development deficits including cardiomyopathies and accessory electrical pathways. How p.S646F interferes with the development of the heart is unknown due to a fundamental lack of understanding regarding Ank-B proteostasis and its role in cardiac differentiation. Initial in silico analyses predicted the p.S646F mutant to be deleterious to the Ank-B protein. Using in vitro techniques, I determined p.S646F mutant reduced levels of Ank-B in H9c2 rat ventricular cardiomyoblasts. Furthermore, haploinsufficiency in mice was previously shown to result in developmental cardiac deficits. I, therefore, hypothesized that p.S646F interferes with Ank-B proteostasis, thereby affecting cardiomyocyte development. I showed that p.S646F destabilized Ank-B in cardiomyoblasts, due to increased degradation via the proteasome. Furthermore, overexpression of p.S646F Ank-B had a significant impact on cellular behaviour including reduced cell viability, and altered expression of cellular differentiation markers. Together these data address critical knowledge gaps with regards to Ank-B protein homeostasis and the role of Ank-B in cardiomyocyte viability and development. These findings inform the diagnosis and treatment of patients with the p.S646F variant, creating potential targeted pathways of intervention, and furthering our understanding of the role of the Ank-B in the development of the heart. / Graduate / 2019-04-26

No description available.

<p>Organelle transport in eukaryotic cells is regulated by a precisely coordinated activity of phosphoinositide lipids, small GTPases, and molecular motors. Despite the extensive study of functional activities of individual regulators, how these activities promote precise deliveries of particular membrane proteins to specific cellular locations remained unclear. Ankyrin-B, which is previously well recognized as a plasma membrane adaptor that assembles diverse specialized plasma membrane domains, exhibited an unexpected role in intracellular transport. This thesis establishes ankyrin-B as a master integrator of the polarized long range organelle transport via direct interactions with Rab GTPase Activating Protein 1 Like (RabGAP1L), phosphatidylinositol 3-phosphate (PI3P) and dynactin 4. In Chapter 2, I identified an ankyrin-B death domain binding partner, RabGAP1L, that specifically interacts with ankyrin-B on intracellular organelles and requires ankyrin-B for its proper localization. In Chapter 3, I demonstrated that ankyrin-B is a PI3P-effector in mouse embryonic fibroblasts (MEFs) and promotes the polarized transport of associated organelles in migrating cells in a RabGAP1L-dependent manner. I continued to investigate what membranes/membrane-associated proteins utilize the ankyrin-B/RabGAP1L pathway in Chapter 4 and identified α5β1-integrin as a cargo whose polarized transport and recycling are ankyrin-B-dependent. I further presented that ankyrin-B, through recruiting RabGAP1L to PI3P-positive/Rab22A-associated endosomes containing α5β1-integrin, promotes polarized recycling of α5β1-integrin in migrating mouse embryonic fibroblasts. In collaboration with James Bear (UNC Chapel Hill), we further demonstrated that this ankyrin-B/RabGAP1L-mediated pathway is required for haptotaxis along fibronectin gradients. In Chapter 5, I elucidated the in vivo interaction between ankyrin-B and RabGAP1L. I demonstrated that ankyrin-B specifically interacts with RabGAP1L at long axon tracts in the brain and at costameres in the skeletal muscle. I also show the phenotypic analysis of ankyrin-B floxDD mice as an initial attempt to determine the physiological function of the ankyrin-B death domain in vivo. Together, this thesis dissects an ankyrin-B-mediated molecular mechanism for polarized endosomal trafficking and α5β1-integrin recycling during directional cell migration, and provides new insights into how phosphoinositide lipids, Rab GTPases, and molecular motor activities are coordinated to control the directional transport of specialized membrane cargos.</p> / Dissertation

Ankyrin B (AnkB) is a scaffolding protein, acting as a bridge between ion channels and cytoskeleton networks. AnkB variants are associated with cognitive disorders including autism spectrum disorder and epilepsy. In the brain, AnkB interacts with Cav2.1, the pore-forming subunit of P/Q type voltage gated calcium channels. However, how AnkB regulates Cav2.1 is not fully understood. Using HEK293T cells, we discovered that AnkB increases Cav2.1 expression levels but does not change Cav2.1 surface levels. AnkB p.S646F increases Cav2.1 to an even greater level of expression, again without impacting Cav2.1 surface levels. Looking at a partial loss of AnkB in glutamatergic neurons, overall Cav2.1 levels decreased at P30 but the synaptosomal fraction was not impacted. Our findings indicate that AnkB plays a role in regulating an intracellular pool of Cav2.1 but does not affect the surface or the synaptosomal pools of Cav2.1. This intracellular pool of Cav2.1 may play an important role in neuronal function and homeostasis, suggesting a mechanism for neuronal pathogenicity of AnkB variants. / Graduate / 2020-08-06

Receptor tyrosine kinases (RTKs) are integral membrane proteins that regulate many functions including cell proliferation, cell survival, and cell death. They have been shown to be responsible for the uncontrolled growth of several cancers. RTKs phosphorylate downstream targets such as phosphatidylinositol 3 kinase (PI3K), a lipid kinase that is made up of two major subunitsp85 and p110. Receptor-mediated endocytosis delivers RTKs from the plasma membrane to late endosomes and lysosomes for degradation. This process is controlled by ESCRT proteins and Rab7. PI3K associates with PDGFR during endocytosis, and PI3K binding sites are necessary for the lysosomal trafficking of PDGFR. The smaller isoforms of the ankyrin 3 (Ank3) proteins bind p85. Ank3 overexpression was shown to increase PDGFR degradation, perhaps by controlling the targeting of PDGFR to late endosomes and lysosomes. Ank3 overexpression also reduced the RTK levels and cell proliferation rates of NIH 3T3 cells. We sought to investigate if cancer cells with RTK overexpression might be deficient in Ank3, and if overexpression of ankyrin 105 (Ank105), one of the smaller isoforms of Ank3, would reduce RTK levels and the tumorigenic properties of cancer cells. Two brain cancer cell lines showed reduced Ank105 levels associated with high RTK levels, while high levels of Ank105 associated with low RTK levels were found in normal brain cells. This suggested a loss of Ank105 in the cancer cells, which may have played a role in the cancer development process. We observed reduced RTK levels and anchorage-independent growth in cancer cells overexpressing HA-Ank105, however, most cells overexpressing a blank vector also showed the same results. An independent effect of the overexpression process was thought to play a role in influencing cell behavior. In the lung cancer cell line HCC827, however, there was significant reduction of anchorage-independent growth that was specific for HA-Ank105. There also appeared to be a significant reduction in the cell proliferation rate of T98G brain cancer cells following transfection with HA-Ank105. Furthermore, those cells overexpressing HA-Ank105 tended to die early in tissue culture, with those that survived losing their HA-Ank105 expression. Overall our results suggest a possible role for Ank105 in downregulating RTK levels and growth properties of cancer cells.

Receptor tyrosine kinases (RTKs) are integral membrane proteins that regulate many functions including cell proliferation, cell survival, and cell death. They have been shown to be responsible for the uncontrolled growth of several cancers. RTKs phosphorylate downstream targets such as phosphatidylinositol 3 kinase (PI3K), a lipid kinase that is made up of two major subunitsp85 and p110. Receptor-mediated endocytosis delivers RTKs from the plasma membrane to late endosomes and lysosomes for degradation. This process is controlled by ESCRT proteins and Rab7. PI3K associates with PDGFR during endocytosis, and PI3K binding sites are necessary for the lysosomal trafficking of PDGFR. The smaller isoforms of the ankyrin 3 (Ank3) proteins bind p85. Ank3 overexpression was shown to increase PDGFR degradation, perhaps by controlling the targeting of PDGFR to late endosomes and lysosomes. Ank3 overexpression also reduced the RTK levels and cell proliferation rates of NIH 3T3 cells. We sought to investigate if cancer cells with RTK overexpression might be deficient in Ank3, and if overexpression of ankyrin 105 (Ank105), one of the smaller isoforms of Ank3, would reduce RTK levels and the tumorigenic properties of cancer cells. Two brain cancer cell lines showed reduced Ank105 levels associated with high RTK levels, while high levels of Ank105 associated with low RTK levels were found in normal brain cells. This suggested a loss of Ank105 in the cancer cells, which may have played a role in the cancer development process. We observed reduced RTK levels and anchorage-independent growth in cancer cells overexpressing HA-Ank105, however, most cells overexpressing a blank vector also showed the same results. An independent effect of the overexpression process was thought to play a role in influencing cell behavior. In the lung cancer cell line HCC827, however, there was significant reduction of anchorage-independent growth that was specific for HA-Ank105. There also appeared to be a significant reduction in the cell proliferation rate of T98G brain cancer cells following transfection with HA-Ank105. Furthermore, those cells overexpressing HA-Ank105 tended to die early in tissue culture, with those that survived losing their HA-Ank105 expression. Overall our results suggest a possible role for Ank105 in downregulating RTK levels and growth properties of cancer cells.

Submitted by Daniella Sodre (daniella.sodre@ufpe.br) on 2015-04-13T13:09:37Z No. of bitstreams: 2 DISSERTAÇÃO Amanda Gabriela Monteiro.pdf: 790791 bytes, checksum: 3eff4891262b8390bd95b7e68ff4d165 (MD5) license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) / Made available in DSpace on 2015-04-13T13:09:37Z (GMT). No. of bitstreams: 2 DISSERTAÇÃO Amanda Gabriela Monteiro.pdf: 790791 bytes, checksum: 3eff4891262b8390bd95b7e68ff4d165 (MD5) license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Previous issue date: 2014-01-09 / A família Drosophilidae abriga mais de 4.200 espécies de pequenas moscas, sendo considerada uma das maiores da ordem Diptera, com destaque para o grupo willistoni do gênero Drosophila, composto por 23 espécies. Nos estudos ecológicos realizados recentemente pelo grupo de pesquisa do Laboratório de Genética da UFPE/CAV, destacamse as espécies crípticas Drosophila willistoni, D. paulistorum e D. equinoxialis e a espécie não críptica Drosophila nebulosa. Merece destaque o fato de D. paulistorum ser constituída de seis semiespécies (Andino-Brasileira, Amazônica, Centro-Americana, Interior, Orinocana e Transicional) o que ilustra os diversos níveis de especiação que existem dentro do grupo, e sua importância para estudos evolutivos. Foi objetivo deste trabalho investigar a variabilidade genética dos genes PlexinB e Ankyrin, presentes no elemento cromossômico F de Müller. Este cromossomo recombinante é resultante da fusão entre o cromossomo dot ancestral da família Drosophilidae (Elemento F) e cromossomo III (Elemento E), evento que ocorreu em todas as espécies do grupo willistoni. De posse dos dados de sequenciamento foram estabelecidas as relações filogenéticas entre as espécies e também entre as semiespécies de D. paulistorum. Fizeram parte dos estudos 28 amostras, coletadas recentemente nos biomas Floresta Amazônicas (Pará e Rondônia), Floresta Atlântica (Pernambuco) e Caatinga (Pernambuco, Ceará e Bahia), ou linhagens de stock centers. O gene PlexinB se destacou como o mais conservado dentro das espécies, enquanto Ankyrin foi bastante variável. Foi detectada uma deleção de 9 pares de bases em todas amostras de D. willistoni e outra de 3 pb em todas D. equinoxialis. Tanto PlexinB quanto Ankyrin permitiram a construção de um bem fundamentado fenograma, com maior similaridade genética entre as amostras de D. paulistorum e D. equinoxialis, depois com D. willistoni ou D. tropicalis, e então com D. nebulosa. A maior diversidade foi observada dentro da superespécie D. paulistorum. Estes resultados abrem novas perspectivas para o estudo e entendimento da dinâmica da especiação, dentro do grupo willistoni de Drosophila.